At a glance
- Originator Merck & Co
- Class Antiglaucomas; Neuroprotectants; Nootropics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 21 Jan 1997 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
- 21 Jan 1997 No-Development-Reported for Glaucoma in USA (Unknown route)